Blood Res.  2016 Mar;51(1):61-63. 10.5045/br.2016.51.1.61.

A case of Pneumocystis jiroveci pneumonia after bendamustine-based chemotherapy for refractory diffuse large B-cell lymphoma

• Ha J
• Jung Y
• Jung Y
• Lee S
• Lee Y
• Woo I

• KMID: 2172747
• DOI: http://doi.org/10.5045/br.2016.51.1.61

Abstract

No abstract available.

MeSH Terms

B-Lymphocytes*
Drug Therapy*
Lymphoma, B-Cell*
Pneumocystis jirovecii*
Pneumocystis*
Pneumonia*

Figure

• 

  Fig. 1 A chest X-ray showed consolidation in right lower lung field (A). Followed-up chest X-ray which was performed 10 days after TMP-SMX treatment showed interval regression of consolidation in right lung field (B).

• 

  Fig. 2 A chest computed tomography (CT) scan revealed newly noted diffuse and multifocal patchy ground glass opacity and consolidation in both lungs (right side predominant).

Reference

1. Obeid KM, Aguilar J, Szpunar S, et al. Risk factors for Pneumocystis jirovecii pneumonia in patients with lymphoproliferative disorders. Clin Lymphoma Myeloma Leuk. 2012; 12:66–69. PMID: 22000698.

2. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc. 2007; 82:1052–1059. PMID: 17803871.

3. Kurokawa T, Kaya H, Yoshida T. Two cases of Pneumocystis jiroveci pneumonia with non-Hodgkin's lymphoma after CHOP-based chemotherapy containing rituximab. J Clin Exp Hematop. 2010; 50:159–162. PMID: 21123974.

4. Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2010; 10:452–457. PMID: 21189660.

5. Kahl BS, Bartlett NL, Leonard JP, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer. 2010; 116:106–114. PMID: 19890959.

6. Klippstein A, Schneider CP, Sayer HG, Höffken K. Pneumocystis carinii pneumonia as a complication of bendamustine monotherapy in a patient with advanced progressive breast cancer. J Cancer Res Clin Oncol. 2003; 129:316–319. PMID: 12756557.

7. Carter SJ, Bernstein SH, Friedberg JW, Barr PM. Pneumocystis jirovecii pneumonia as a complication of bendamustine in a patient receiving bendamustine plus rituximab for marginal zone lymphoma. Leuk Res. 2011; 35:e223–e224. PMID: 21824654.

8. Reinbolt RE, Alam S, Layman R, Shapiro C, Lustberg M. Pneumocystis jiroveci pneumonia in an atypical Host. Clin Breast Cancer. 2012; 12:138–141. PMID: 22133356.

9. Hosoda T, Yokoyama A, Yoneda M, et al. Bendamustine can severely impair T-cell immunity against cytomegalovirus. Leuk Lymphoma. 2013; 54:1327–1328. PMID: 23072371.

10. Ito K, Okamoto M, Ando M, et al. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma. Leuk Lymphoma. 2015; 56:1123–1125. PMID: 24828861.

11. Brugger W, Ghielmini M. Bendamustine in indolent non-Hodgkin's lymphoma: a practice guide for patient management. Oncologist. 2013; 18:954–964. PMID: 23900001.